SCHEMBL162718

SCHEMBL162718

CN(C)Cc1cc[c]cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.56
ALDH1A1 P00352 2/20 0.56
TSHR P16473 2/20 0.56
TAAR1 Q96RJ0 2/20 0.48
NOS1 P29475 2/20 0.41
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
HDAC3 O15379 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
AOC3 Q16853 1/20 0.36
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
GSR P00390 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27625032 0.97 HRH3 (0.54) HRH3ALDH1A1TSHRTAAR1NOS1
SCHEMBL3133159 0.86 HRH3 (0.74) HRH3ALDH1A1TSHRTAAR1NOS1
SCHEMBL8721626 0.81 HRH3 (0.48) HRH3ALDH1A1TSHRTAAR1NOS1
SCHEMBL659509 0.80 HRH3 (0.82) HRH3ALDH1A1TSHRTAAR1NOS1
SCHEMBL18227681 0.80 MEN1 (0.47) HRH3ALDH1A1TSHRTAAR1
SCHEMBL20768136 0.78 CHRNB2 (0.47) HRH3ALDH1A1TSHRCHRNB2CHRNA4
SCHEMBL7357073 0.77 HRH3 (0.33) HRH3ALDH1A1TSHRAOC3POLB
SCHEMBL5448129 0.77 ADRA2B (0.42) HRH3ALDH1A1TSHRHDAC6AOC3
SCHEMBL2645780 0.77 ALDH1A1 (0.54) ALDH1A1TSHRAOC3LMNAGAA
SCHEMBL27816979 0.77 CARM1 (0.35) HRH3ALDH1A1TSHRLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 868 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
US-11753408-B2 Compounds and method for blocking transmission of malarial parasite THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-12 US claimed
WO-2023070120-A1 KETOAMIDES FOR TREATING MALIGNANCY BIOTHERYX, INC. (US) 2023-04-27 WO claimed
US-20220389009-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GFB (ABC), LLC 2022-12-08 US claimed
CN-114787160-A Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors 因赛特公司 2022-07-22 CN claimed
US-11345712-B2 Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications BIOTHERYX, INC. (US) 2022-05-31 US claimed
CN-114502543-A Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof 拜欧斯瑞克斯公司 2022-05-13 CN claimed
WO-2022011274-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GOLDFINCH BIO, INC. (US) 2022-01-13 WO claimed
US-11192854-B2 Method for producing semicarbazide compound TOKUYAMA CORPORATION (JP) 2021-12-07 US claimed
EP-3898627-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 Incyte Corporation (US) 2021-10-27 EP claimed
WO-1996039393-A1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-12 WO claimed
CN-1133603-A Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same PROCTER & GAMBLE (US) 1996-10-16 CN claimed
US-5532255-A Adhesion receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-07-02 US claimed
WO-1996000708-A1 METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-01-11 WO claimed
WO-1994005651-A1 5-SUBSTITUTED 3-THIOPHENE SULFONAMIDES AS ANTIGLAUCOMA AGENTS ALLERGAN, INC. (US) 1994-03-17 WO claimed
EP-0582304-A2 Methods of producing amino butene derivatives FUJIREBIO Inc. (JP) 1994-02-09 EP claimed
EP-0049173-B1 PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL DERIVATIVES CONTAINING THEM SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-07-03 EP claimed
US-4385058-A HISTAMINE H2-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1983-05-24 US claimed
EP-0049173-A2 Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1982-04-07 EP claimed
US-4276295-A VASODILATORS, HYPOTENSIVE, ANTIATHEROSCLEROTIC Ishikawa, Masayuki (JP) 1981-06-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 HRH3 3763/4885ALDH1A1 1318/4885TSHR 4243/4885
US-11753408-B2 Compounds and method for blocking transmission of malarial parasite PLK1, HSP90B1, CEP170 HRH3 2849/4885ALDH1A1 1866/4885TSHR 4265/4885
US-11192854-B2 Method for producing semicarbazide compound SALL4, SHH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HRH3 31/4885ALDH1A1 900/4885TSHR 560/4885
US-20220389009-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 CDK5, CDK5R1, PKD1 HRH3 4071/4885ALDH1A1 2375/4885TSHR 4297/4885
US-11345712-B2 Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications HSP90B1, EIF4EBP1, SERPINA6 HRH3 4130/4885ALDH1A1 4668/4885TSHR 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.